Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
JCO Precision Oncology
|
January 23, 2023
Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data
Carsten Bokemeyer, Noman Paracha, Ulrik Lassen, et al.
The Oncologist
|
March 24, 2023
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
Albrecht Stenzinger, Brian Cuffel, Noman Paracha, et al.
European Urology Oncology
|
May 1, 2025
Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials
Christopher J D Wallis, Sara Ekberg, Alicia K Morgans, et al.
European Urology
|
June 21, 2025
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial
Marc-Oliver Grimm, Matthew Smith, Maha Hussain, et al.
JCO Precision Oncology
|
June 29, 2023
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis
Ulrik Lassen, Carsten Bokemeyer, Jesus Garcia-Foncillas, et al.
European Urology Oncology
|
April 9, 2026
Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials
Alicia K Morgans, Sara Ekberg, Martin Boegemann, et al.
Cancers
|
April 12, 2022
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
Jesus Garcia-Foncillas, Carsten Bokemeyer, Antoine Italiano, et al.
Journal of Medical Economics
|
March 6, 2019
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
Umang Ondhia, H J Conter, Scott Owen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2025
Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis
Neal Shore, Alicia K Morgans, Martin Boegemann, et al.
Journal of Comparative Effectiveness Research
|
January 6, 2026
Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer
Neal Shore, Alicia K Morgans, Noman Paracha, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
JCO Precision Oncology
|
January 23, 2023
Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data
Carsten Bokemeyer, Noman Paracha, Ulrik Lassen, et al.
The Oncologist
|
March 24, 2023
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
Albrecht Stenzinger, Brian Cuffel, Noman Paracha, et al.
European Urology Oncology
|
May 1, 2025
Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials
Christopher J D Wallis, Sara Ekberg, Alicia K Morgans, et al.
European Urology
|
June 21, 2025
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial
Marc-Oliver Grimm, Matthew Smith, Maha Hussain, et al.
JCO Precision Oncology
|
June 29, 2023
Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis
Ulrik Lassen, Carsten Bokemeyer, Jesus Garcia-Foncillas, et al.
European Urology Oncology
|
April 9, 2026
Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials
Alicia K Morgans, Sara Ekberg, Martin Boegemann, et al.
Cancers
|
April 12, 2022
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
Jesus Garcia-Foncillas, Carsten Bokemeyer, Antoine Italiano, et al.
Journal of Medical Economics
|
March 6, 2019
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
Umang Ondhia, H J Conter, Scott Owen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2025
Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis
Neal Shore, Alicia K Morgans, Martin Boegemann, et al.
Journal of Comparative Effectiveness Research
|
January 6, 2026
Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer
Neal Shore, Alicia K Morgans, Noman Paracha, et al.
Page
of 4